Buy or sell: ICICI Direct recommends two stocks for this week
Wed, Jul 10, 2024 7:53 PM

Buy or sell: ICICI Direct recommends two stocks for this week

A Flip by Shubhangi Gupta
Get it on Google Play
Indian stock market indices fell, with Sensex dropping 426.87 points to 79,924.77 and Nifty 50 falling 108.75 points to 24,324.45, due to profit booking after reaching higher levels. The Bank Nifty index also declined 0.72% to 52,189.30. ICICI Direct recommended buying Alkem Labs at ₹5060-5085 with a target price of ₹5410 and selling Asian Paints India at ₹2925-2935 with a target price of ₹2780.

More great flips

Analysis-Geopolitics is back to break markets' stride

Analysis-Geopolitics is back to break markets' stride

Global markets are reeling from geopolitical concerns, with investors fleeing potential flashpoints like Taiwan's stock market and seeking havens like gold, which hit an all-time high. The escalating uncertainty is prompting investors to reassess portfolio risk levels, with nearly half the globe voting this year and results underscoring a shift in mood. Assets under management are being adjusted.

Open Flip
UPI going global, Project Nexus to accelerate the process, says Survey

UPI going global, Project Nexus to accelerate the process, says Survey

The Reserve Bank of India is working to internationalize the Unified Payments Interface (UPI) by collaborating with various countries to link India's Fast Payments System with their respective systems for cross-border payments. This aims to replace card payments and other corporate channels for international remittances, making transactions faster and more cost-effective.

Open Flip
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche

Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche

Pfizer and Roche Holdings, two powerful pharmaceutical companies, are developing weight loss drugs, potentially disrupting the market dominated by Novo Nordisk and Eli Lilly. Pfizer's danuglipron is in phase 1 clinical trials, but previous studies showed high patient discontinuation rates and limited efficacy. Roche's CT-996, also in phase 1, has shown promising results.

Open Flip

Join our Smart Investment Community

More than 2 Million users are using FlipItMoney to stay updated about the business and finance world! Join FlipItMoney now and take smart investment decisions!
Icon